Table 1.
Baseline Clinical Characteristics of the Overall Cohort and Those who Died and did not die During the 1-Year Follow up.
| Variable | Survivors n = 136 (%) |
Nonsurvivors N = 43 (%) |
P value |
|---|---|---|---|
| Age (Mean ± SD) | 60.3 ± 16.1 | 66.2 + 13.4 | .03 |
| Female | 64 (49.2) | 28 (65.1) | .05 |
| Race | .32 | ||
| • White | 69 (53.5) | 30 (69.8) | |
| • Black | 47 (36.4) | 10 (23.3) | |
| • Hispanic | 9 (7) | 2 (4.7) | |
| • Other | 4 (3.1) | 1 (2.3) | |
| PE severity | .09 | ||
| • Low risk | 36 (27.7) | 8 (18.6) | |
| • Submassive risk | 86 (66.2) | 28 (65.1) | |
| • High risk | 8 (6.2) | 7 (16.3) | |
| Thrombolysis | .15 | ||
| • Systemic | 2 (1.6) | 2 (4.8) | |
| • CDT | 18 (14.1) | 2 (4.8) | |
| Embolectomy | .35 | ||
| • Surgical | 5 (4) | 1 (2.3) | |
| • Percutaneous | 2 (1.6) | 2 (4.6) | |
| BMI (kg/m2) (Mean ±SD) | 32.6 + 9.1 | 28.5 + 9.8 | .01 |
| PESI score(Mean ±SD) | 106 + 46.5 | 152 + 45.5 | <.01 |
| Hypertension | 63 (51.6) | 21 (47.5) | .72 |
| Diabetes | 28 (23.7) | 10 (23.3) | 1 |
| CKD | 7 (5.8) | 8 (19) | .03 |
| Cancer | 25 (20.5) | 29 (67.4) | <.01 |
| HF | 11 (9) | 9 (21.4) | .05 |
| CAD | 17 (14) | 7 (16.7) | .8 |
| COPD | 6 (4.9) | 6 (14) | .08 |
| Prior Stroke | 15 (12.3) | 2 (4.7) | .2 |
| Prior PE | 8 (6.6) | 10 (23.3) | .008 |
| Acute DVT | 80 (63) | 29 (69) | .58 |
| Lactate (Mean ±SD) | 1.9 + 1.1 | 3.9 + 4.1 | <.01 |
| Troponin (Mean ±SD) | 0.5 + 1.2 | 2.2 + 7 | .01 |
| BNP (Mean ±SD) | 198.5 + 242.9 | 436.1 + 646.6 | .002 |
| PAI-1 (µg/ml) | 58.9 + 35.9 | 76.1 + 46.5 | .02 |
| TAFI (% of normal) | 114.7 + 25.5 | 104.2 + 35.6 | .07 |
| A2A (% of normal) | 89 + 36.3 | 75.6 + 23 | .03 |
Abbreviations: PE, pulmonary embolism; CDT, catheter-directed thrombolysis; BMI, body mass index; PESI, pulmonary embolism severity index; CKD, chronic kidney disease; HF, heart failure; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; DVT, deep vein thrombosis; BNP, brain natriuretic peptide; PAI, plasminogen activator inhibitor; TAFI, thrombin activatable fibrinolysis inhibitor; A2A, alpha 2 antiplasmin.